Celcuity Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CELC | ORIC | RLAY | AVBP | EXEL | IDYA | |
|---|---|---|---|---|---|---|
| Market cap | 3.39B | 968.12M | 3.95B | 665.16M | 17.75B | 3.12B |
| P/E (TTM) | — | — | — | — | 21.8 | — |
| Forward P/E | -141.3 | -5.5 | -11.0 | -3.6 | 17.0 | -7.9 |
| Price/book | -265.3 | 2.5 | 5.5 | 1.8 | 9.7 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −6.53% | −22.54% | +176.11% | −28.97% | +79.12% | +5.63% |
| Today | −0.69% | −2.61% | +3.38% | +3.61% | +0.61% | +3.29% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CELC news ›Celcuity: Stronger Clinical Evidence, Much Lower Valuation
Celcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. Learn more about CELC stock here. - Celcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and…
Celcuity, Inc. (NASDAQ:CELC) Stock Has Consensus Target Price of $152.57
Posted by Sarita Garza on Oct 27th, 2026 Check Out Our Latest Stock Analysis on Celcuity Celcuity stock opened at $65.80 on Tuesday. Celcuity has a 1-year low of $53.54 and a 1-year high of $151.02. The company has a debt-to-equity ratio…
Celcuity says Revtorpyk boosts progression-free survival in breast cancer
Phase 3 VIKTORIA-1 results show Revtorpyk beat Vijoice in advanced breast cancer PFS and response duration. - Celcuity said that updated results from a cohort of the phase 3 VIKTORIA-1 trial found that Revtorpyk (gedatolisib) plus…
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Celcuity (CELC) Shares Dip Despite Strong VIKTORIA-1 Trial Results in Advanced Breast Cancer
Shares of Celcuity dropped 0.49% during the regular trading day, settling at $65.25—a decrease of $0.32. After-hours activity saw the stock slide an additional 1.39%, bringing the price down to $64.34. The decline occurred amid a session…
Celcuity initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Li Watsek initiated coverage of Celcuity (CELC) with an Overweight rating and $140 price target Published first on T... Celcuity initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald analyst Li…
Cantor starts Celcuity at Overweight on multi-billion sales potential
Cantor Fitzgerald initiated coverage of Celcuity (CELC) with an Overweight rating and $140 price target Celcuity is a commercial-stage oncology... Cantor starts Celcuity at Overweight on multi-billion sales potential Cantor Fitzgerald…
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and…
Celcuity Inc. Announces Appointment of David W. Gryska to Board of Directors and Member of the Audit Committee and Compensation Committee, Effective October 1, 2026
Celcuity Inc. announced the appointment of David W. Gryska to its Board of Directors to fill the resulting vacancy, effective immediately, On October 1, 2026, for a term extending through the date of... announced the appointment of David W…
Transcript : Celcuity Inc., Q2 2026 Earnings Call, Aug 13, 2026
Presentation Operator MessageOperator Good afternoon, ladies and gentlemen. Welcome to Celcuity Second Quarter 2026 Financial Results Conference Call and Webcast. [Operator Instructions] I would Transcript : Celcuity Inc., Q2 2026 Earnings…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- markets.businessinsider.com3
- defenseworld.net1
- ibtimes.com.au1
- moneycheck.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.